Alector, Inc.

Alector, Inc. is a clinical-stage biotechnology company that develops therapies for neurodegenerative diseases, focusing on areas with significant unmet medical needs. The company's work is based on advancements in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and disruptions in immune and neuronal pathways. Alector aims to develop product candidates that address diseases through targeted mechanisms, such as removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function. The company is advancing a portfolio of programs focused on genetically validated targets, supported by its expertise in drug development, protein engineering, and antibody discovery. A key part of its strategy is the Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier (BBB) delivery technology designed to improve central nervous system exposure for various therapeutic types. This platform is being refined to enable effective brain delivery at clinically practical doses of antibodies, enzymes, and siRNA therapeutics. Alector also invests in biomarkers and biomarker assays to guide patient selection, demonstrate target and pathway engagement, and assess biological impact in clinical trials. Alector's portfolio includes nivisnebart (formerly AL101/GSK4527226), an investigational progranulin (PGRN)-elevating antibody. This candidate has completed enrollment in a placebo-controlled, double-blinded Phase 2 study for early Alzheimer's disease (AD) under a July 2021 Collaboration and License Agreement with Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK). The company's wholly owned programs include lead candidates in preclinical development for a brain-penetrant anti-amyloid beta antibody for Alzheimer's disease and a brain-penetrant GCase enzyme replacement therapy for Parkinson's disease (PD) and Lewy body dementia (LBD). Alector is also developing brain-penetrant siRNA programs targeting tau for Alzheimer's disease, α-synuclein for Parkinson's disease, and NLRP3, which has potential applications across multiple neurodegenerative conditions. Nivisnebart is an investigational human recombinant monoclonal antibody designed to elevate PGRN levels in the brain, with pharmacokinetic and pharmacodynamic properties potentially suitable for treating prevalent neurodegenerative diseases.